September 2020

Granted Project “CDIFFVAC “(EUROSTARS)

“Next Generation Vaccines for Multi-Resistant Bacteria”.

Partners: Proxi Biotech ApS, Cellvax SAS, LiteVax B.V.

July 2020

Granted Project “BACTOVAC” (EU TRANSVAC2)

“Safety and immunogenicity of a CMS-adjuvanted, newly developed toxoid-based vaccine against C. difficile infection in non-rodent species”. Partners: Proxi Biotech ApS, Institut national de la Recherche agronomique (INRA), LiteVax B.V.

May 2020


“Immunogenicity of recombinant SARS-CoV-2 Spike Protein Subunits plus a novel, potent adjuvant in Non-Rodent Species”; Possibilities of a Single-Low-Dose Vaccine against Coronavirus Infection”

Partners: ImmunoPrecise Antibodies, Institut de Recerca i Tecnologia Agroalimentàries (IRTA), LiteVax B.V.


April 2020

Granted Project “INDIGO” (EU/INDIA, HORIZON 2020)

“Effective and affordable flu vaccine for the globe”

LiteVax receives EU Horizon 2020 grant for the development of a next generation of flu vaccines for the globe.



Februari 2020

Granted Project “TREAT-HER2” (EUROSTARS)

“Treatment enabled by REcombinant Advanced immunotherapy Technologies for HER2 positive tumours”.

Partners: AdaptVac, University of Copenhagen, Expres2ion, Biomedical Primate Research Centre, LiteVax.


March 2019

Granted Project “MucoVAC” (EUROSTARS)

Development of a sublingual mucosal immunization technology platform for needle-free vaccination”.

Partners: InStar Technologies a.s., Helmholtz – Zentrum für Infektionsforschung GmbH, Timeline Bioresearch AB, Chimera Biotec GmbH, LiteVax B.V.

May 2018

LiteVax Joins Dutch Trade Mission to India

For the third time in 2018 LiteVax visited India and joined the Dutch Trade Mission. Prime Minister Mark Rutte and four Ministers were present to support the strategic relationships and economic cooperation. During this important event LiteVax signed 3 MoU's with Indian companies for vaccine development.

Netherlands Trade Mission India 2018 Netherlands Trade Mission India 2018 Netherlands Trade Mission India 2018 Netherlands Trade Mission India 2018
December 2016


One of the predecessor of LiteVax LVX adjuvant proved to be superior to Freunds’ Complete/Incomplete Adjuvant in large animal species (PMID: 27693642)


July 2016


LiteVax received an EU commissioned grant from ADITEC (European Union's Seventh Framework Programme Grant Agreement No: 280873) to determine immunological performance of LVA in mice.
February 2014


Patent of new adjuvant molecules filed (WO 2016/013938).
July 2013


LiteVax moved to Pivot Park in Oss, i.e. the former R&D facilities of MSD.
April 2012

CoVaccine BV

LiteVax BV moved into lab facilities of the University of Utrecht and acquired the assets of CoVaccine BV, a company founded some 10 years earlier focusing on synthetic adjuvants for human and veterinary application.
January 2012


Together with Radboud University Nijmegen Medical Centre (Nijmegen, NL), Xbrane Biosciences AB (Stockholm, SE), Drug Discovery Factory BV (Amsterdam, NL) LiteVax BV formed a consortium and received a EUROSTARS grant for the development of an intranasal, universal pneumococcal vaccine.